The aim of this study was to show that soluble recombinant (sr) proteins can mimic blood group antigens and be used to screen human sera for blood‐group‐specific antibodies. The blood of all pregnant women and pretransfusion patients should be screened for blood‐group‐specific antibodies to identify and monitor pregnancies at risk of haemolytic disease of the foetus and newborn (HDFN), and to prevent haemolytic transfusion reactions. Current antibody screening and identification methods use human red blood cell panels, which can complicate antibody identification if more than one antibody specificity is present. COS‐7 cells were transfected to produce sr forms of the extracellular domains of the red blood cell membrane proteins that express Kell, Duffy or Lutheran blood group antigens. These sr proteins were used to screen for and identify anti‐Kell, anti‐Duffy or anti‐Lutheran blood‐group‐specific allo‐antibodies in human sera by haemagglutination inhibition and in solid‐phase enzyme‐linked immunosorbent assays (ELISAs). There is a positive correlation (correlation coefficient 0·605, P value 0·002) between antibody titre by standard indirect antiglobulin test (IAT) and signal intensity in the ELISA test. This work shows that sr proteins can mimic blood group antigens and react with human allogeneic antibodies, and that such proteins could be used to develop solid‐phase, high‐throughput blood group antibody screening and identification platforms.